By Sneha S K and Gnaneshwar Rajan

Jan 13 (Reuters) - Thermo Fisher Scientific's ( TMO )

pharmaceutical services business has won a number of contracts

to help its customers move production from Europe or Asia ‌to the

U.S., the medical equipment maker's CEO, Marc Casper, said ​on

Tuesday.

"There's a very big focus on reshoring more ‍production

and activity to the U.S.," Casper ⁠said at the ⁠J.P. Morgan

Healthcare Conference, adding that the trend is going to ‌be a

tailwind in 2027 and ​2028.

U.S. President Donald Trump has pushed pharma companies to

onshore domestic manufacturing to the ⁠U.S.

Although enforcement of a ‍proposed ​100% tariff on imported

medicines is delayed, the policy has already prompted

fast-tracked projects, price cuts and direct-to-consumer ‍sales.

Thermo last year acquired Sanofi's manufacturing

site in Ridgefield, New Jersey, to produce critical medicines

for the French drugmaker.

"Part of the reason we acquired the Sanofi site was really a

capital expansion, to ​be ‍able to help customers do that

(reshore)," Casper said.

He also said that biotech funding is improving. "The

pharmaceutical ​industry feels very confident about how they are

working with the U.S. administration, and there's confidence in

investing in their pipeline ... So actually we see an improving

set of end markets."

Overall, Thermo Fisher's messaging was constructive and the

company ​did a fine job expressing optimism without raising the

bar for 2026, said Evercore ISI analyst Vijay Kumar.